Mice repopulated with human hematopoietic cells are a powerful tool for the study of human hematopoiesis and immune function in vivo. However, existing humanized mouse models cannot support development of human innate immune cells, including myeloid cells and natural killer (NK) cells. Here we describe two mouse strains called MITRG and MISTRG, in which human versions of four genes encoding cytokines important for innate immune cell development are knocked into their respective mouse loci. The human cytokines support the development and function of monocytes, macrophages and NK cells derived from human fetal liver or adult CD34 + progenitor cells injected into the mice. Human macrophages infiltrated a human tumor xenograft in MITRG and MISTRG mice in a manner resembling that observed in tumors obtained from human patients. This humanized mouse model may be used to model the human immune system in scenarios of health and pathology, and may enable evaluation of therapeutic candidates in an in vivo setting relevant to human physiology.
A r t i c l e s Small-animal models such as mice are frequently used for in vivo studies of mammalian, especially human, immune responses. However, fundamental differences in immune function exist between species 1,2 and frequently, knowledge gained from mouse studies cannot be translated to humans.
One promising approach for studying human immune function in vivo is to use immunodeficient mice transplanted with human hematopoietic stem and progenitor cells 2, 3 . However, the development and function of several human immune cell types, such as monocytes, macrophages and NK cells, is largely defective in currently available models of humanized mice 2 . More specifically, human monocytes and macrophages are present at low frequency 4, 5 , and although a report showed that these cells are functional 4 , another report identified functional impairments and an immature phenotype of human monocytes 6 . The maturation, function and homeostasis of human NK cells are also defective in existing humanized mice 7, 8 . These limitations highlight a need to develop humanized mice that model a more complete and functional human innate immune system.
The defects in human innate immune cell development in existing humanized mice are most likely due to limited reactivity of mouse cytokines with corresponding human cytokine receptors 9 . Several strategies to attempt to circumvent this issue by delivering human cytokines to the mouse host have been described 10, 11 ; some rely on administered exogenous cytokines 7 or cytokine-encoding plasmids 5, 12 , whereas others use introduced transgenes encoding human cytokines [13] [14] [15] . However, high systemic concentrations of cytokines can result in artifactual effects such as the mobilization and exhaustion of hematopoietic stem cells 13 or supraphysiological cell frequencies.
The approach of knocking in human cytokine genes to replace their mouse counterparts has the advantage of ensuring appropriate tissue-, cell-and context-specific expression of the human cytokine 10 . Furthermore, in the scenario of homozygous human cytokine knockin mice, if the human cytokine is not fully reactive with the corresponding mouse cytokine receptor, mouse cell populations dependent on signaling from that cytokine may exhibit numerical or functional defects; these defects confer an additional competitive advantage on transplanted human cells 10 . This knock-in gene replacement strategy has been used to 'humanize' several cytokine-encoding genes. For example, humanization of the gene encoding thrombopoietin (Thpo, also known as Tpo) had resulted in enhanced maintenance of functional human hematopoietic stem cells capable of multilineage differentiation, of sustaining long-term high engraftment in the bone marrow (BM) and of serial transplantation 16 ; humanization of the genes encoding interleukin 3 (Il3) and granulocyte-macrophage colony-stimulating factor 2 (GM-CSF; Csf2) had lead to the development of functional human alveolar macrophages 17 ; and humanization of the Csf1 gene, which encodes M-CSF, had resulted in increased numbers of human monocytes or macrophages in multiple tissues 18 . Although each of these gene replacements improved the development and function of individual cell types ( Supplementary Table 1 
),
A r t i c l e s they did not result in a complete and robust human myelomonocytic system in a mouse.
Modeling of the complete human monocyte and macrophage compartment is important because monocytes and macrophages are important in tissue homeostasis, inflammation and tumorigenesis, and in the response to infectious agents 19, 20 . Two general classes of macrophages have been defined on the basis of their gene expression profile, secretome composition and effector activity 21 : the classically activated M1 subtype that displays proinflammatory and microbicidal activities, and the alternatively activated M2 subtype characterized by immunoregulatory, antiparasite and tissue-repair roles. That said, this dichotomy is probably an oversimplification, and a spectrum of functionally distinct macrophage subsets likely exists. Regardless, the M1-M2 paradigm of macrophage differentiation is relevant to a number of human pathologies, including cancer [21] [22] [23] . For example, M1-like tumor-infiltrating macrophages show tumoricidal activity, whereas M2-like macrophages in the tumor microenvironment promote tumor growth by providing proliferative, antiapoptotic and proangiogenic signals; these signals also enable cancer-cell egress from primary tumors and formation of metastases 23, 24 . Clinical observations indicate that myeloid cells infiltrate several types of tumors, and in most cases, high densities of infiltrating macrophages correlate with poor patient prognosis [23] [24] [25] [26] .
To develop a humanized mouse model to study this and other human macrophage-related phenomena, we hypothesized that a synergy between multiple humanized cytokines would enable the full recapitulation of human myeloid development and function in the mouse. Therefore, we generated immunodeficient Rag2 −/− Il2rg −/− mice 27 in which the genes encoding human M-CSF 18 , human interleukin 3 (IL-3) and GM-CSF 17 , and human thrombopoietin 16 are knocked in to their respective mouse loci 10 ; these mice are named MITRG for the encoded proteins M-CSF, IL-3/GM-CSF and TPO in the Rag2 −/− Il2rg −/− background. MISTRG mice also bear a bacterial artificial chromosome (BAC) transgene encoding human SIRPα 28 . SIRPα binds to CD47 and the resulting signal suppresses phagocytosis of CD47-expressing cells. Because human CD47 constitutively expressed on human cells binds efficiently to the mouse BAC transgene-encoded human SIRPα, this transgene enables mouse phagocytes to 'tolerate' and not engulf engrafted human cells 28, 29 . MITRG and MISTRG mice are highly permissive for human hematopoiesis. In particular they harbor functional human myelomonocytic cells exhibiting subset diversity and numbers unprecedented in all previously described humanized mouse models and closely resembling those in humans. Using these mice, we found that human monocytes act as a source of IL-15 trans-presentation, and support the development and function of human NK cells. We show that human myeloid cells infiltrated a human tumor grafted onto these mice; these tumor-infiltrating cells exhibited an immunosuppressive M2-like phenotype, and their presence correlated with tumor growth. By providing a more complete and functional model of the human innate immune system, MITRG and MISTRG mice may enable application of humanized mice to new areas of translational research.
RESULTS

Hematopoietic engraftment in MITRG and MISTRG mice
We sublethally irradiated newborn MISTRG mice and their MITRG littermates (lacking the human SIRPA transgene), and transplanted these mice with human fetal liver-derived CD34 + cells, following a standard protocol 27 (Online Methods). Rag2 −/− Il2rg −/− mice that have the same genetic background (129 × Balb/c N2) but lack all the humanized alleles, and commercially available nonobese diabetic severe combined immunodeficient Il2rg −/− (NSG) mice served as controls.
Blood engraftment (percentage of human CD45 + cells (hCD45 + cells) among all CD45 + cells (including human and mouse CD45); Fig. 1a,b and Supplementary Fig. 1a ) in NSG recipients was higher than in Rag2 −/− Il2rg −/− recipients, as previously reported 28, 30 . The percentage of blood hCD45 + cells was similar in MISTRG, MITRG and NSG mice, which suggested that humanization of the four cytokine genes overcomes the need to induce phagocytic tolerance through SIRPα-CD47 cross-reactivity 28, 29, 31 , possibly owing to defects in the mouse innate response caused by the absence of mouse cytokines. We selected mice with at least 10% hCD45 + cells in the blood for subsequent experiments (Supplementary Fig. 1b ). In bone marrow (BM), percentages of hCD45 + cells averaged ~90% in MITRG and MISTRG recipients (Fig. 1a,c and Supplementary Fig. 1c-e ), and the high efficiency of engraftment in the BM was also independent of SIRPα-CD47 interaction. MISTRG mice can also be engrafted with hCD34 + cells isolated from cord blood or from peripheral blood of adult donors after mobilization by G-CSF ( Supplementary Fig. 2) .
To test the capacity of humanized cytokines to support human hematopoiesis in more competitive conditions, we transplanted human fetal CD34 + cells into nonirradiated MISTRG mice. This protocol resulted in hCD45 + cells in the blood and BM of all recipients, and half of the mice showed chimerism as high as the highest levels measured in recipients engrafted after X-ray preconditioning ( Fig. 1d,e ). These results show that humanization of multiple cytokines creates a microenvironment in which human hematopoiesis can almost completely displace mouse hematopoiesis in BM and obviate the need for pathology-inducing irradiation.
Functional human myeloid cells in MITRG and MISTRG mice
Next we assessed the capacity of MITRG and MISTRG mice to support human myelopoiesis. Human myeloid cells (hCD33 + ) were present in significantly higher proportions in the blood and BM of MITRG and MISTRG mice compared to Rag2 −/− Il2rg −/− and NSG recipients ( Fig. 2a and Supplementary Fig. 3a-c) . The increased proportion of myeloid cells in MITRG and MISTRG mice resulted in a blood composition resembling that of human blood, which is rich in myeloid cells and radically different from that of lymphoid-rich mouse blood 1,2 ( Fig. 2b and Supplementary Fig. 3d ). We observed a similar composition in the blood of MISTRG mice engrafted without irradiation ( Supplementary Fig. 3e ). Human myeloid cells were also present in high numbers (exceeding those in NSG recipients by approximately tenfold) in nonlymphoid tissues such as lung, liver and colon of MITRG and MISTRG mice, as shown by immunohistochemistry (hCD68 + cells; Fig. 2c ) and flow cytometry (hCD33 + ; Supplementary  Fig. 3f,g) . Although both human monocytes (CD33 hi SSC lo CD66 − ) and neutrophils (CD33 + SSC hi CD66 + ) were present in the BM of MITRG and MISTRG mice ( Supplementary Fig. 4a,b) , the human myeloid cell populations in peripheral blood of MITRG and MISTRG mice were composed mostly of monocytes ( Supplementary Fig. 4c ); this observation suggests that terminal differentiation, egress from the BM or peripheral survival of human neutrophils is still suboptimal in this mouse environment. MISTRG mice also supported the development of human eosinophils (Siglec-8 + SSC hi ) and basophils (FcεRIα + ) in the BM and blood ( Supplementary Fig. 4d-g) , and to a lesser extent in the lung (data not shown). Human dendritic cells (including conventional and plasmacytoid dendritic cells) were also present in MISTRG mice and underwent maturation after in vivo stimulation with lipopolysaccharide (LPS), which suggested that these cells were functional ( Supplementary Fig. 5 ).
In humans, three subsets of monocytes have been phenotypically and functionally described 19,32 based on differential expression of A r t i c l e s CD14 and CD16 (CD14 + CD16 − , CD14 + CD16 + and CD14 dim CD16 + ). All three subpopulations were present in the blood as well as lymphoid and nonlymphoid tissues (for example, lung and liver) of MITRG and MISTRG mice ( Fig. 2d,e and Supplementary Fig. 6a,b) . In contrast, NSG mice harbored a lower frequency of total myeloid cells and very few CD14 dim CD16 + cells. Staining with additional markers including CD33, CD11b, CD115, CD62L and CX 3 CR1 indicated that in most cases the monocyte subpopulations found in MISTRG mice closely resembled their counterparts in human peripheral blood and BM ( Fig. 2f and Supplementary Fig. 7 ).
Next we assessed the function of human monocytes in MITRG and MISTRG mice. Human CD14 + CD16 − and CD14 + CD16 + monocytes isolated from BM of MITRG mice produced tumor necrosis factor alpha (TNFα) and IL-6 in response to stimulation with LPS (TLR4 agonist) and R848 (TLR7/8 agonist) ( Fig. 3a,b ). In addition, CD14 + CD16 − and CD14 + CD16 + cells from MITRG mice phagocytosed GFP-expressing Escherichia coli in vitro; CD14 dim CD16 + monocytes had limited phagocytic ability ( Fig. 3c) , which reflected the physiological properties of the corresponding subpopulations in human blood 32 . After injection with LPS or infection with Listeria monocytogenes (Listeria) or influenza A, we detected higher amounts of human TNFα, IL-6 and interferon β (IFN-β) in the tissues of MITRG or MISTRG mice compared to NSG mice ( Fig. 3d-f ). These results demonstrate that the human monocyte subsets that develop in MITRG and MISTRG mice are functional in vitro and in vivo.
Drawbacks of the high overall human engraftment levels as well as human myeloid cell function are defective development of mouse red blood cells (RBCs), particularly after irradiation, and phagocytosis of these mouse RBCs by human macrophages. As the development of human RBCs is also inefficient, human hematopoietic cell engraftment in MITRG and MISTRG mice promotes progressive destruction of mouse RBCs and anemia ultimately ensues; the incidence of anemia in these mice correlates with engraftment levels higher than ~60% hCD45 + cells in the blood. This leaves a period of ~2-3 weeks to perform experiments on healthy mice before the development of anemia (Online Methods). For experiments requiring longer periods of analysis, the onset of anemia can be delayed, and the lifespan of engrafted MITRG and MISTRG mice can be extended. One way this can be achieved is by injecting human cells into recipient mice without irradiating the recipient mice. Indeed, nonirradiated MISTRG mice with human CD45 + cell engraftment levels of 60-80% in the blood were healthy and did not show any signs of anemia 12 weeks after transplantation (for example, the mice in Fig. 1e ). Alternatively, a lower number of human fetal liver CD34 + donor cells can be injected; on a population basis, this leads to lower engraftment levels. Lastly, adult human CD34 + cells, which engraft less efficiently than human Supplementary Fig. 1c ) from b (n = 12-16 mice; *P < 0.05, Tukey test; Supplementary Fig. 1d,e) . npg fetal liver CD34 + cells, can be used. Notably, even with lower overall engraftment levels, MITRG and MISTRG mice retain all of their advantages over NSG mice, such as superior myelopoeisis.
Functional human NK cells in MISTRG mice
By producing cytokines, myeloid cells can support the development and differentiation of other immune cells. As such, we investigated whether the improved human myeloid compartment in MISTRG mice could be a source of human cytokines, such as IL-15 transpresented by IL-15Rα, which are essential for development of human NK cells 33 . Human mRNA transcripts encoding IL-15 and IL-15Rα were more than tenfold more abundant in MITRG and MISTRG compared to NSG liver and lung ( Fig. 4a and Supplementary Fig. 8a ). Next we measured the abundance of human mRNA encoding IL-15 and IL-15Rα in purified human cell populations. Expression of human mRNA encoding IL-15Rα was higher in human myeloid cells (hCD33 + ) than nonmyeloid cells (hCD33 − ) ( Fig. 4b) . Human CD14 + CD16 + monocytes expressed particularly high amounts of mRNA encoding IL-15 and IL-15Rα ( Fig. 4b) .
Next we confirmed expression of human IL-15Rα protein on the surface of human myeloid cells from MISTRG mice by flow cytometry ( Supplementary  Fig. 8b ). Although human CD14 + CD16 + monocytes did not express higher amount of surface IL-15Rα than CD14 + CD16 − monocytes, high background staining made it difficult to accurately compare surface IL-15Rα expression between the two subsets. Based on these findings, we analyzed the development of human immune cells dependent on IL-15 trans-presentation, such as NK cells, in MITRG and MISTRG mice 33, 34 . Efficient development of human NK cells in existing humanized mouse models requires injection of exogenous human IL-15 and IL-15Rα 7,12 because mouse IL-15 and IL-15Rα are not sufficient to support human NK cells in vivo. As previously reported 7,8,12 , we observed very few human NK cells (hNKp46 + hCD3 − ) 
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A r t i c l e s in engrafted NSG mice (Fig. 4c,d and Supplementary Fig. 9a,b) .
In contrast, we readily detected human NK cells (at tenfold higher numbers compared to NSG mice) in multiple tissues of engrafted MISTRG mice (Fig. 4c,d and Supplementary Fig. 9a,b) .
With the exception of BM, MITRG mice contained fewer human NK cells than MISTRG mice, most likely owing to the previously reported requirement for human SIRPα for the survival of human NK cells in the periphery 31 . The hNKp46 + hCD3 − cells in MISTRG mice represented bona fide NK cells because like human NK cells they expressed the NK cell surface markers CD94, CD161 and killer inhibitory receptors (KIRs) (Supplementary Fig. 10a,b) . Expression of the maturation marker CD16 was higher on the surface of NK cells from MISTRG mice compared to NSG mice, which suggested that human IL-15 and IL-15Rα also support maturation of NK cells in MISTRG mice ( Supplementary Fig. 10c,d) .
It is not known which cell(s) is responsible for trans-presentation of IL-15 in vivo in humans, but human myeloid cells can support human NK cell proliferation in vitro 7 . To test whether trans-presentation of human IL-15 by human monocytes or macrophages underlies the improved human NK cell development in MISTRG mice, we treated MISTRG mice with liposome-encapsulated clodronate to deplete phagocytic cells. Depletion of phagocytic cells significantly reduced the number of human NK cells, but not human T cells, in MISTRG mice (Fig. 4e,f) , which suggested that human monocytes Next we examined the function of human NK cells in MISTRG mice. NK cells defend against pathogens by killing cells that lack surface MHC class I expression 35 and by producing IFN-γ 36 . Compared to human NK cells from NSG mice, NK cells from MISTRG mice expressed higher amounts of the lytic granule protein perforin (Fig. 5a,b) and exhibited significantly enhanced cytotoxic activity against human cells lacking MHC class I in vivo (Fig. 5c ). In addition, expression of mRNA encoding human IFN-γ was more than tenfold higher in the liver of MISTRG than NSG mice 2 d after Listeria infection (Fig. 5d) , and more NK cells from Listeria-infected MISTRG mice than NSG mice produced higher amounts of human IFN-γ (without ex vivo restimulation) ( Fig. 5e,f) . NK cells in MISTRG mice also showed more degranulation (measured by plasma membrane exposure of CD107a) after Listeria infection (Fig. 5f) . These findings indicate that the efficient human myeloid cell development in MISTRG mice enables efficient development, differentiation and function of human NK cells.
T and B lymphocyte function in MITRG and MISTRG mice
Whereas the human cytokines expressed in MISTRG were principally aimed at improving the human innate immune cell development, we also characterized adaptive immune cells (T and B lymphocytes) in MITRG and MISTRG mice. Human T and B cells were present in MITRG and MISTRG mice at lower frequencies than in NSG mice, owing to the relative increase in myeloid cells in MITRG and MISTRG mice (Fig. 2b, and Supplementary Figs. 11a and 12a) . B cells mostly displayed an immature phenotype, as shown by the expression of the CD10, CD24 and CD38 markers, in both NSG and MISTRG recipients (Supplementary Fig. 11b,c) . Likely as a consequence of this B cell immaturity 37 , humoral immune responses were low in both strains of mice (Supplementary Fig. 11d) . The majority of CD4 and CD8 T cells in the blood of NSG and MISTRG displayed a naive surface phenotype (CCR7 + CD45RA + ; Supplementary Fig. 12b,c) . Human T cells in MISTRG mice were functional because like human NK cells they produced IFN-γ in response to Listeria infection (Supplementary Fig. 12d,e ).
Tumor infiltration in MITRG and MISTRG mice
In addition to their roles in infection and inflammation, monocytes and macrophages can acquire immunosuppressive functions important for the resolution of inflammation and for tissue repair. These anti-inflammatory properties, if exhibited by tumor-infiltrating macrophages, can provide a survival advantage to evolving tumors 22, 23 . We thus examined the influence of human myeloid cells on tumor development in MITRG and MISTRG mice. We used the human melanoma cell line Me290 as a tumor model 38 . In agreement with clinical observations showing that myeloid cells infiltrate tumors in several solid tumors [23] [24] [25] [26] , we detected more human myeloid cell infiltration in tumors in MITRG and MISTRG mice than in NSG mice, as shown by the expression of human PTPRC mRNA (encodes CD45) and ITGAM mRNA (encodes CD11b) in subcutaneously grafted Me290 tumors (Fig. 6a) . Cells expressing the macrophage markers CD163 and CD14 were abundant in tumors in MISTRG mice and in tumors from human patients but were almost undetectable in the tumors in NSG mice (Fig. 6b,c; and Supplementary Fig. 13 ). CD163 + cells also expressed low levels of HLA-DR and high levels of CD206 (Fig. 6b,d) , an immunophenotype generally associated with M2-like macrophages.
We hypothesized that M2-like macrophages infiltrating tumors in MISTRG mice may promote tumor growth. Supporting this hypothesis, the tumors in engrafted MITRG and MISTRG mice, which are heavily infiltrated by human CD163 + HLA-DR low CD206 + macrophages, were significantly larger than tumors in NSG mice, which are not infiltrated by human macrophages; tumors in engrafted NSG mice are similar in size to tumors in non-engrafted NSG or MITRG and MISTRG mice (Fig. 6e,f) . One way macrophages support tumor growth is by producing cytokines or enzymes that promote vascularization and immune suppression. VEGF is one such molecule 39, 40 , and to test 
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A r t i c l e s whether it was involved in tumor growth in MISTRG mice, we treated the mice with the human-VEGF inhibitor Avastin. This treatment completely inhibited the tumor growth in engrafted MITRG and MISTRG mice ( Fig. 6f) , suggesting that engrafted cells, potentially including myeloid cells, in MITRG and MISTRG mice support tumor growth through a mechanism that involves VEGF activity. These results show that MITRG and MISTRG mice recapitulate the role of human macrophages in tumor development and fulfill a critical need for models that enable study of the interaction between human tumors and human macrophages in vivo.
DISCUSSION
Despite their great promise for translational research, existing humanized mouse models do not permit efficient development of human innate immune cells. The MITRG and MISTRG model described here overcomes this major limitation. As such, MITRG and MISTRG mice may uniquely enable study of fundamental questions regarding the biology of the human immune system, in vivo modeling of human diseases and preclinical in vivo testing of new drug candidates.
The high efficiency of human hematopoietic cell engraftment (for example, human cells almost completely replace mouse cells in BM) and robust development of diverse subsets of human innate immune cells in MITRG and MISTRG mice is due to the synergistic effect of cytokines that support successive steps and multiple lineages of human hematopoiesis as well as to the secondary provision of additional cytokines by human cells themselves. The fact that MISTRG can be efficiently engrafted without irradiation illustrates the advantage of the combined replacement of multiple mouse cytokine genes with their human counterparts. The absence of mouse cytokines results in defects in mouse cell populations (in particular mouse hematopoietic stem cells and phagocytic cells) and induces a state of genetic preconditioning.
MITRG and MISTRG mice will facilitate the engraftment of hematopoietic cells derived from the peripheral blood and/or BM of humans with disease. This will allow the reconstitution of a patient-derived immune system and may permit the study of low-proliferative, primary human hematopoietic malignancies, such as myelodysplastic syndromes or myeloproliferative neoplasia, that thus far have proven difficult to efficiently engraft immunodeficient mice 41, 42 . npg Furthermore, a human immune system can be combined with cotransplantation of diseased tissues from the same donor; this may be relevant to autoimmune diseases and cancer. This will create a personalized model in which the interaction of the patient's immune system with cancer cells or autoimmune target tissues can be studied in vivo. Moreover, the effect of drugs on the immune system and co-transplanted tissues can be evaluated preclinically, and treatments could be tailored to the individual patient in a personalized manner. An implication of our tumor xenograft experiments is that the outcome of antitumor drug treatment is markedly affected by the presence or absence of tumor-infiltrating human immune cells. Therefore, the role of nontumor cells, including but not limited to human myeloid cells, should be considered and carefully evaluated in the screening of candidate antitumor drugs.
MITRG and MISTRG mice will also enable study of the human innate immune system in acute and chronic inflammation as well as in infectious disease. The function of monocytes or macrophages is highly dependent on in vivo contexts that cannot be easily modeled in vitro. For example, CD16 + monocytes, which develop in the MISTRG model but not in other humanized mouse models, are expanded in humans in inflammatory settings including those caused by HIV infection and atherosclerosis 43 . However, the functional importance of CD16 + monocytes in these settings is unknown; MITRG and MISTRG mice may enable the investigation of causal relationships between CD16 + monocytes and human inflammatory disease. Macrophages are also prominent in humans infected with bacteria including Mycobacterium tuberculosis 44 . Further improvements of the adaptive immune system function in MITRG and MISTRG mice (see below) should enable study of the interaction between human macrophages, CD4 + T cells and M. tuberculosis in vivo. Standard nonhumanized mice do not represent this complex human disease faithfully. Other fundamental questions that may be answered using the MITRG and MISTRG mouse model include the ontogenic origin of tissue macrophages versus monocyte-derived macrophages 45 , the trafficking of these cells in response to inflammation or infection, and the mechanisms of differentiation and effector function of M1 versus M2 macrophages 46 .
Finally, MISTRG mice will allow study of the role of human NK cells in vivo, for example, in the context of cancer and viral infections 47 .
Although MISTRG mice represent a marked improvement over existing humanized mouse models, they also have two drawbacks. First, as mentioned earlier, development and survival of both mouse and human RBCs is suboptimal in MITRG and MISTRG mice. This problem will need to be addressed in the future by genetic strategies to either protect mouse RBCs from phagocytosis by human cells or to support the development and survival of human RBCs.
The other limitation of MITRG and MISTRG mice, similarly to other models, is their relatively weak adaptive immune responses, with low cytotoxic and humoral immune responses, particularly a low frequency of somatic hypermutation and class-switching in B cells. Adaptive immunity might be improved by several approaches, including expression of human MHC elements in mice or use of the BMliver-thymus approach in which human fetal tissues are transplanted along with human CD34 + cells 48, 49 . The BM-liver-thymus approach results in more robust adaptive immune responses because T cells develop and are selected in a human thymic tissue. A non-mutually exclusive approach would be humanizing additional cytokine genes in recipient mice. By combining multiple strategies, humanized mouse models may fully recapitulate functional human innate and adaptive immune responses. Such mouse models may enable an even wider variety of basic and preclinical research applications.
METHODS
Methods and any associated references are available in the online version of the paper.
Note: Any Supplementary Information and Source Data files are available in the online version of the paper.
